[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:skin-squamous-cell-carcinoma:soluble-epidermal-growth-factor-receptor":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Skin Squamous Cell Carcinoma","Soluble Epidermal Growth Factor Receptor",4,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04429542","Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.748848Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06960395","Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:27.743517Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[32],"Phase 1\u002FPhase 2","2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z"]